Payment overview · 2025
General Payments
$158,387.84
254 reported records · 22 companies
Healthcare provider profile · identity verified
John E Anderson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NASHVILLE, TN · NPI 1003801788
Verified facts
What the public records show
CMS Open Payments records show John E Anderson, MD received $158,387.84 in general payments during 2025 across 254 reported records.
Lilly USA, LLC accounted for 52.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 15 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Eli Lilly and Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 176 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83,638.81 | 52.8% | 113 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $36,065.71 | 22.8% | 22 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16,542.41 | 10.4% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $11,078.92 | 7.0% | 33 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $6,074.99 | 3.8% | 3 | 2025 |
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $3,600.00 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $380.26 | 0.2% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $214.83 | 0.1% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $161.18 | 0.1% | 10 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $98.95 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.46 | 0.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.69 | 0.1% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.36 | 0.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.11 | 0.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.60 | 0.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.10 | 0.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.08 | 0.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.99 | 0.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.40 | 0.0% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $29.50 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.36 | 0.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.13 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,805.00 | 75 |
| Consulting Fee | $19,617.35 | 7 |
| Travel and Lodging | $7,098.99 | 37 |
| Honoraria | $6,633.00 | 2 |
| Food and Beverage | $4,303.53 | 129 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,900.00 | 3 |
| Long term medical supply or device loan | $29.97 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82,836.07 | 110 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $34,815.71 | 21 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16,542.41 | 14 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $11,048.95 | 32 | 2025 |
Source payment records
|
|||||
| OMNIPOD Normalized: omnipod |
Device | Insulet Corporation | $6,074.99 | 3 | 2025 |
Source payment records
|
|||||
| ADLYXIN Normalized: adlyxin |
Biological | SANOFI-AVENTIS U.S. LLC | $1,250.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $167.74 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $159.62 | 8 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $140.70 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $124.48 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $120.76 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $98.95 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.46 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.46 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $85.69 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $84.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.12 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.36 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.11 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.60 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.70 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.99 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.20 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 63 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 137 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 73 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 11 recipient NPIs · example record 1186556234 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| Eli Lilly and Company Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 176 supporting records · 33 recipient NPIs · example record 1186466331 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 706 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 157 |
| Lisinopril | Lisinopril | 532 | 155 |
| Pantoprazole Sodium | Pantoprazole Sodium | 506 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 116 |
| Simvastatin | Simvastatin | 360 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 354 | 104 |
| Metformin Hcl | Metformin Hcl | 315 | 95 |
| Losartan Potassium | Losartan Potassium | 307 | 90 |
| Alprazolam | Alprazolam | 294 | 59 |
| Omeprazole | Omeprazole | 273 | 80 |
| Meloxicam | Meloxicam | 222 | 72 |
| Trazodone Hcl | Trazodone Hcl | 220 | 76 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 69 |
| Sertraline Hcl | Sertraline Hcl | 208 | 65 |
| Gabapentin | Gabapentin | 190 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 57 |
| Carvedilol | Carvedilol | 173 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 163 | 45 |
| Clonazepam | Clonazepam | 162 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 32 |
| Mounjaro | Tirzepatide | 153 | 21 |
| Allopurinol | Allopurinol | 152 | 47 |
| Furosemide | Furosemide | 147 | 50 |
| Jardiance | Empagliflozin | 137 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 136 | 40 |
| Potassium Chloride | Potassium Chloride | 124 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 32 |
| Methylprednisolone | Methylprednisolone | 97 | 77 |
| Donepezil Hcl | Donepezil Hcl | 96 | 29 |
| Ramipril | Ramipril | 95 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 94 | 24 |
| Farxiga | Dapagliflozin Propanediol | 91 | 24 |
| Metformin Hcl Er | Metformin Hcl | 87 | 26 |
| Diazepam | Diazepam | 84 | 14 |
| Trulicity | Dulaglutide | 84 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 56 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 22 |
| Glimepiride | Glimepiride | 75 | 21 |
| Ozempic | Semaglutide | 73 | 14 |
| Lovastatin | Lovastatin | 72 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 20 |
| Tramadol Hcl | Tramadol Hcl | 70 | 18 |
| Bupropion Xl | Bupropion Hcl | 69 | 25 |
| Estradiol | Estradiol | 69 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Alendronate Sodium | Alendronate Sodium | 66 | 23 |
| Ezetimibe | Ezetimibe | 64 | 22 |
| Eliquis | Apixaban | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 61 | 19 |
| Azithromycin | Azithromycin | 59 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 15 |
| Valacyclovir | Valacyclovir Hcl | 53 | 20 |
| Atenolol | Atenolol | 49 | 14 |
| Montelukast Sodium | Montelukast Sodium | 48 | 15 |
| Finasteride | Finasteride | 47 | 13 |
| Spironolactone | Spironolactone | 46 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 17 |
| Fenofibrate | Fenofibrate | 40 | 13 |
| Mirtazapine | Mirtazapine | 40 | 15 |
| Lansoprazole | Lansoprazole | 39 | 12 |
| Primidone | Primidone | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Famotidine | Famotidine | 37 | 12 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 11 |
| Ibuprofen | Ibuprofen | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Linzess | Linaclotide | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 18 |
| Ketoconazole | Ketoconazole | 22 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 11 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $158,387.84 · 254 records | Lilly USA, LLC | ADLYXIN, AIRSUPRA, BREZTRI, CAPVAXIVE, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OMNIPOD, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error